S55746 (Servier 1)

Our first collaboration with Servier started in 2007 and has progressed well over the last eight years. Bcl-2 is the most advanced programme from this collaboration, with S55746, a selective Bcl-2 inhibitor, the first drug candidate stemming from an ongoing collaboration between Vernalis and Servier aimed at discovering anticancer drug candidates selective for individual Bcl-2 family members.

S55746 entered a Phase I study in June 2014, triggering a €1 million milestone payment to Vernalis. Servier has subsequently licensed the development and commercialisation rights to Novartis. Vernalis' commercial terms remain unchanged and so will continue to receive fees from Servier for research as well as sums for achieving research and clinical milestones, together with a potential share of eventual commercial sales through royalties.

 

Latest News

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

Servier and Vernalis plc are pleased to announce the achievement of two research milestones and one clinical milestone in their oncology drug discovery collaboration, triggering a total payment of €2 million to Vernalis.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch